Starpharma Holdings (Starpharma Holdings) Minority Interest : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Starpharma Holdings Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Starpharma Holdings's minority interest for the quarter that ended in Dec. 2023 was $0.00 Mil.

Starpharma Holdings Minority Interest Historical Data

The historical data trend for Starpharma Holdings's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Starpharma Holdings Minority Interest Chart

Starpharma Holdings Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Minority Interest

Get a 7-Day Free Trial

Starpharma Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Minority Interest	Get a 7-Day Free Trial															-	-	-	-	-

Starpharma Holdings Minority Interest Calculation

Starpharma Holdings (Starpharma Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Starpharma Holdings Ltd (OTCPK:SPHRY) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

SPHRF:USA PQ6:Germany SPL:Australia

Address

4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067

Website

https://www.starpharma.com

Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.